Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma

Muhammed Ashraf Memon, Shahjahan Khan, Rossita Mohamad Yunus, Richard Barr, Breda Memon, Muhammed Ashraf Memon, Shahjahan Khan, Rossita Mohamad Yunus, Richard Barr, Breda Memon

Abstract

Objectives: The aim was to conduct a meta-analysis of the randomized evidence to determine the relative merits of laparoscopic assisted (LADG) and open (ODG) distal gastrectomy for proven gastric cancer.

Data sources and review methods: A search of the Medline, Embase, Science Citation Index, Current Contents, and PubMed databases identified all randomized clinical trials (RCTs) that compared LADG and OGD and were published in the English language between January 1990 and the end of June 2007. The meta-analysis was prepared in accordance with the Quality of Reporting of Meta-analyses (QUOROM) statement. The eight outcome variables analysed were operating time, blood loss, retrieval of lymph nodes, oral intake, hospital stay, postoperative complications, tumor recurrence, and mortality. Random effects meta-analyses were performed using odds ratios (OR) and weighted mean differences (WMD).

Results: Four trials were considered suitable for meta-analysis. A total of 82 patients underwent LADG and 80 had ODG. For only one of the eight outcomes, the summary point estimates favoured LADG over ODG; there was a significant reduction of 104.26 ml in intraoperative blood loss for LADG (WMD, -104.26, 95% confidence interval (CI) -189.01 to -19.51; p = 0.0159). There was however a 83.08 min longer duration of operating time for the LADG group compared with the ODG group (WMD 83.08, 95% CI 40.53 to 125.64; p = 0.0001) and significant reduction in lymph nodes harvesting of 4.34 lymph nodes in the LADG group (WMD -4.3, 95% CI -6.66 to -2.02; p = 0.0002). Other outcome variables such as time to commencement of oral intake (WMD -0.97, 95% CI -2.47 to 0.54; p = 0.2068), duration of hospital stay (WMD -3.32, 95% CI -7.69 to 1.05; p = 0.1365), rate of complications (OR 0.66, 95% CI 0.27 to 1.60; p = 0.3530), mortality rates (OR 0.94, 95% CI 0.21 to 4.19; p = 0.9363), and tumor recurrence (OR 1.08, 95% CI 0.42 to 2.79; p = 0.8806) were not found to be statistically significant for either group. However, for commencement of oral intake, duration of hospital stay, and complication rate, the trend was in favor of LADG.

Conclusion: LADG was associated with a significantly reduced rate of intraoperative blood loss, at the expense of significantly longer operating time and significantly reduced lymph node retrieval compared to its open counterpart. Mortality and tumor recurrence rates were similar between the two groups. Furthermore, time to commencement of oral intake, postprocedural discharge from hospital, and perioperative complication rate, although not significantly different between the two groups, did suggest a positive trend toward LADG. Based on this meta-analysis, the authors cannot recommend the routine use of LADG over ODG for the treatment of distal gastric cancer. However, significant limitations exist in the interpretation of this data due to the limited number of published randomised control trials, the small sample sizes to date, and the limited duration of follow up. Further large multicentre randomized controlled trials are required to delineate significantly quantifiable differences between the two groups.

References

    1. Surg Endosc. 2005 Feb;19(2):168-73
    1. J Clin Epidemiol. 2000 May;53(5):477-84
    1. J Am Coll Surg. 2004 Jun;198(6):933-8
    1. Transfusion. 1995 Sep;35(9):760-8
    1. Crit Care. 2004;8 Suppl 2:S18-23
    1. Surgery. 1996 May;119(5):483-6
    1. BMJ. 1997 Sep 13;315(7109):629-34
    1. Scand J Surg. 2007;96(1):35-40
    1. World J Surg. 1987 Aug;11(4):418-25
    1. Ann Surg. 1989 Nov;210(5):596-602
    1. Ann Surg. 1991 Jun;213(6):651-3; discussion 653-4
    1. Surg Laparosc Endosc. 1994 Apr;4(2):146-8
    1. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001964
    1. Jpn J Surg. 1981 Mar;11(2):127-39
    1. Ann Surg. 2005 Feb;241(2):232-7
    1. Surg Endosc. 1998 Sep;12(9):1131-6
    1. Surgery. 2002 Jan;131(1 Suppl):S306-11
    1. Surg Oncol. 2007 Aug;16(2):85-98
    1. Surgery. 1994 Jun;115(6):707-12
    1. Control Clin Trials. 1996 Feb;17(1):1-12
    1. Cancer. 1989 Nov 15;64(10):2053-62
    1. Br J Surg. 1993 Oct;80(10):1252-4
    1. Lancet. 1999 Nov 27;354(9193):1896-900
    1. Surg Endosc. 2005 Sep;19(9):1172-6
    1. J Clin Oncol. 2004 Jul 15;22(14):2767-73
    1. N Engl J Med. 1999 Mar 25;340(12):908-14
    1. Transfusion. 1991 May;31(4):318-23
    1. Lancet. 1996 Apr 13;347(9007):984-5
    1. Br J Cancer. 1999 Mar;79(9-10):1522-30
    1. Surgery. 1993 Aug;114(2):389-97; discussion 397-9

Source: PubMed

3
Abonneren